CN102366480B - Medicine for treating diabetes and preparation method thereof - Google Patents
Medicine for treating diabetes and preparation method thereof Download PDFInfo
- Publication number
- CN102366480B CN102366480B CN 201110289631 CN201110289631A CN102366480B CN 102366480 B CN102366480 B CN 102366480B CN 201110289631 CN201110289631 CN 201110289631 CN 201110289631 A CN201110289631 A CN 201110289631A CN 102366480 B CN102366480 B CN 102366480B
- Authority
- CN
- China
- Prior art keywords
- medicine
- diabetes
- tea
- active component
- rhododendron
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 103
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 99
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 229940079593 drug Drugs 0.000 title claims description 23
- 241001122767 Theaceae Species 0.000 claims abstract description 41
- 235000013616 tea Nutrition 0.000 claims abstract description 41
- 235000015091 medicinal tea Nutrition 0.000 claims abstract description 15
- 239000011449 brick Substances 0.000 claims abstract description 10
- 210000000582 semen Anatomy 0.000 claims description 15
- 241000003857 Parmelia saxatilis Species 0.000 claims description 14
- 241000208422 Rhododendron Species 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000469 ethanolic extract Substances 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000007560 sedimentation technique Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 abstract description 40
- 239000008280 blood Substances 0.000 abstract description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 210000002700 urine Anatomy 0.000 abstract description 11
- 230000006870 function Effects 0.000 abstract description 9
- 210000003734 kidney Anatomy 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 6
- 230000007812 deficiency Effects 0.000 abstract description 4
- 208000004880 Polyuria Diseases 0.000 abstract description 3
- 210000004185 liver Anatomy 0.000 abstract description 3
- 238000010791 quenching Methods 0.000 abstract description 3
- 230000000171 quenching effect Effects 0.000 abstract description 3
- 230000035922 thirst Effects 0.000 abstract description 3
- 206010020710 Hyperphagia Diseases 0.000 abstract description 2
- 210000001124 body fluid Anatomy 0.000 abstract description 2
- 239000010839 body fluid Substances 0.000 abstract description 2
- 210000004072 lung Anatomy 0.000 abstract description 2
- 206010036067 polydipsia Diseases 0.000 abstract description 2
- 208000022530 polyphagia Diseases 0.000 abstract description 2
- 241000219482 Lithops Species 0.000 abstract 1
- 241000245165 Rhododendron ponticum Species 0.000 abstract 1
- 241000674503 Urtica triangularis Species 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 26
- 239000008103 glucose Substances 0.000 description 26
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 26
- 241000700159 Rattus Species 0.000 description 15
- 102000004877 Insulin Human genes 0.000 description 13
- 108090001061 Insulin Proteins 0.000 description 13
- 229940125396 insulin Drugs 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 230000001603 reducing effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 229940123208 Biguanide Drugs 0.000 description 5
- 208000013016 Hypoglycemia Diseases 0.000 description 5
- 229940122355 Insulin sensitizer Drugs 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 150000004283 biguanides Chemical class 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 150000001467 thiazolidinediones Chemical class 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 229940100389 Sulfonylurea Drugs 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 229960004580 glibenclamide Drugs 0.000 description 4
- 230000010030 glucose lowering effect Effects 0.000 description 4
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 4
- 229940125697 hormonal agent Drugs 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 4
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 239000003390 Chinese drug Substances 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 206010016326 Feeling cold Diseases 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 241000219422 Urtica Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- QMNAQPMXDMLOLD-UHFFFAOYSA-N 6-methyl-4-oxo-5,6-dihydrothieno[2,3-b]thiopyran-2-sulfonamide Chemical compound S1C(C)CC(=O)C2=C1SC(S(N)(=O)=O)=C2 QMNAQPMXDMLOLD-UHFFFAOYSA-N 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 229940118148 Aldose reductase inhibitor Drugs 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 206010018045 Gastroptosis Diseases 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 239000009022 Jinqi Substances 0.000 description 1
- 206010024604 Lipoatrophy Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 244000270834 Myristica fragrans Species 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 241001081833 Myristicaceae Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 239000008882 Tang Maikang Substances 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010046607 Urine abnormality Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003288 aldose reductase inhibitor Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000001610 euglycemic effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229960001764 glibornuride Drugs 0.000 description 1
- RMTYNAPTNBJHQI-LLDVTBCESA-N glibornuride Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)N[C@H]1[C@H](C2(C)C)CC[C@@]2(C)[C@H]1O RMTYNAPTNBJHQI-LLDVTBCESA-N 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960003468 gliquidone Drugs 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- -1 muscle Substances 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003243 phenformin Drugs 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 229960001753 phenformin hydrochloride Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229960003611 pramlintide Drugs 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000009874 shenqi Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a medicine for treating diabetes. The medicine is a Tibetan medicine, is also called Jiumei No. 1 diabetes tea and is composed of an active component or the active component and pharmaceutically acceptable accessories, wherein, the active component is prepared from rhododendron anthopogonoide, mutmeg, lithops, urtica triangularis and brick tea according to a certain weight ratio. The medicine can be made into a medicinal tea type oral preparation, including bulk medicinal tea, bagged medicinal tea and decocted medicinal tea. The medicine provided in the invention has the functions of nourishing liver and kidney, tonifying qi, moistening lung, generating body fluid and quenching thirst, and is used for treating diabetes. In Tibetan medicine, the medicine is applicable to diabetes symptoms caused by disorder of Long, e.g., polydipsia, polyphagia, polyuria, macies, urine sugar and elevation of blood sugar levels. In traditional Chinese medicine, the medicine is applicable to diabetes caused by deficiency of both qi and yin.
Description
[technical field]
The present invention relates to a kind of medicine (for a long time U.S. No. 1 diabetic tea) for the treatment of diabetes and preparation method thereof, it is a kind of Tibetan medicine, belongs to the field of Chinese medicines.
[background technology]
Diabetes are a kind of common metabolism endocrinopathyes, and World Health Organization (WHO) classifies them one of as ten large difficult disease.Sickness rate is high, and the trend that rises is year by year arranged; According to statistics, India is present the first in the world diabetes big countries, has patient more than 4,000 ten thousand; China occupies second, and patient 3,000 ten thousand is arranged; There is patient more than 1,000 ten thousand in the 3rd, the U.S.; The WHO estimation, by 2005, the diabetes mellitus in China people will reach 5,000 ten thousand; Developed country more than 60 years old crowd nearly 10% be diabetics, China estimates more than 60 years old that in the crowd, diabetics reaches more than 8%; There is scholarly forecast China might become the first in the world diabetes big countries after India, this is not only because the Chinese population radix is maximum, also because Chinese Economy Development is quick, the compatriots overweight people that life is improved rapidly increases suddenly, and the obese people becomes diabetes Susceptible population; Type ii diabetes accounts for 90%～95% of diabetics total number of persons, and diabetes account for front 5 of the cause of death, and it is one of serious threat people ' s health disease.
The investigation discovery that diabetes mellitus in China association is up-to-date, the onset diabetes rate of China is up to 9.7%, and national diabetes patient is near one hundred million.China has surmounted India becomes diabetes the first big countries.
Diabetes rejuvenation trend is obvious, and onset diabetes increases the fastest in " cause type " personage of 30～45 years old.In the adult more than 20 years old, the diabetes prevalence of age markization is 9.7%, and the ratio of prediabetes is more up to 15.5%, and being equivalent to just has a hyperglycemia state person in every four adults.
China is since reform and opening-up, and people's lives are greatly improved, but following, the diabetes that are known as affluenza also become a kind of commonly encountered diseases, frequently-occurring disease gradually.Over nearly 30 years, the progress of the relevant diabetes control in the whole world is very rapid, China is quite a few to the combination of Chinese and Western medicine research of diabetes control, but significantly break through seldom, compare with external progress and have a long way to go, its reason is many-sided, but that one of them is science is not strong, therefore is difficult to have breakthrough.
Diabetes have become the fourth-largest cause of the death of the mankind, and the whole world has 3,800,000 people of surpassing to die from diabetes and complication thereof every year.The whole world has 2.46 hundred million diabeticss at present.China over nearly 20 years the onset diabetes rate increased more than 5 times, be one of global fastest-rising country.
Over nearly 30 years, the progress of the relevant diabetes control in the whole world is very rapid, China is quite a few to the combination of Chinese and Western medicine research of diabetes control, but significantly break through seldom, compare with external progress and have a long way to go, its reason is many-sided, but that one of them is science is not strong, therefore is difficult to have breakthrough.And the research of pure Tibetan medicine treatment diabetes yet there are no any report.
1, external research to the prevention and treatment in Chinese and western diabetes:
Few to the prevention and treatment in Chinese and western diabetes study abroad, only there are 4 pieces to the research of Radix Ginseng as the american diabetes association annual meeting that has in June, 2,003 10,000 multi-experts to participate in.
2, the current situation and existing problems analysis of domestic prevention and treatment in Chinese and western diabetes study:
Look back China's prevention and treatment in Chinese and western diabetes study in recent decades, although some good achievements are also arranged, often do not take the formal international conference interchange of getting on, thus unknown to the public in the world.And more be some low-level repetitive operation, thereby science is not strong.
According to statistics, China has 6,000 ten thousand above diabeticss at present, at present to diabetes particularly diabetic complication there is no so far effective method.
So high onset diabetes rate expedites the emergence of out the diabetic market that has a high potential.The diabetic field has also become the emphasis that each large medicine enterprise goes on an expedition.2008, global diabetes market total sales volume was up to 24,000,000,000 dollars, and in global diabetes medicament, the oral medicine market share is a little more than insulin preparation.
TCM treatment of diabetes has long history, particularly over nearly 30 years, along with the develop rapidly of modern science, adopts the method for the combination of Chinese and Western medicine, and the treatment of diabetes has been had irreplaceable advantage.
According to statistics, diabetics accounts for 80% by the mortality rate that cardiovascular and cerebrovascular disease causes, and makes its life expectancy reduce 1/3.Diabetics merges blood fat rising person more than 80%, and blood viscosity rising person reaches 90%.
Chinese medicine is slow to the therapeutical effect of diabetes, but belongs to the category that effects a permanent cure, and when blood glucose descends, body constitution is synchronously strengthened, and chronic complicating diseases is had preventive and therapeutic action preferably.
The traditional Chinese medical science thinks, the deficiency of YIN is the pathogenetic essence of glycosuria, insufficiency of the spleen be diabetes do not heal basic, blood stasis is the key that diabetic complications produces.Chinese medicine can be invigorated blood circulation the yin nourishing invigorating the spleen and benefiting QI and be combined dexterously, thereby diabetes fundamentally are effectively treated.Use Chinese medicine can make blood glucose, glucose in urine long-term stability in normal range.
The integral body of Chinese medicine is transferred and can be strengthened patient's body constitution in blood sugar lowering, corrects sugar, protein and fat metabolic disturbance, regulates number or the affinity of Insulin receptor INSR, to increase target cell to the sensitivity of insulin, the antagonism insulin resistant.
The integrally-regulated of Chinese medicine can prevent and treat the generation of diabetes multiple complications effectively.The diabetics majority exists that blood viscosity increases, hyperlipidemia and platelet aggregation rate increase these factors, has caused the basis of the concurrent cardiovascular and cerebrovascular disease of diabetics, peripheral angiopathy and important organ damage.Chinese medicine can reduce blood viscosity and blood fat etc. by benefiting QI for activating blood circulation, thereby prevent and treat complication in blood sugar lowering.
Tibetanmedicine calls diabetes " Jing Nisagu " disease, the general translations of Chinese " urine eliminating mass ".So-called " Jing Nisagu ", " capital Buddhist nun " means frequent micturition, and " Sa Gu " refers to consume the liquid of the muddiness of physical ability, that is to say that frequency of micturition, cloudy urine, consumption physical ability are the substitutive characteristics of primary disease." eight warps of medical science will originally be released " carries: " if ask this why because of, this be hindered by diet etc. and ' Baconic ' dissolve bladder.The thing that addles (waste matter), perspiration, oils and fats, precise and tiny elite in body also can jeopardize ' red bar ' in body and blood etc. under the diet of discomfort, thus, the thing that addles (waste matter) in body, perspiration etc. all can be sneaked into urine, cause urine muddy, and people's physical ability is subdued.Therefore and grand in body also can make the large material of human body ' seven ' bladder that runs off, turn to the urine eliminating external, thereby subdue physical ability." " ' Jing Nisagu ' its disease is seen: weak drowsiness, hyperhidrosis and companion's abnormal flavour are become thin, and hair and onyx are uninteresting simple and unadorned, and in mouthful, normal sense sweet taste and oropharynx are extremely dried, have a liking for cold drink, and the dysphoria with feverish sensation in the chest palms and soles urine is turbid, and urine mark place often has the insecticide such as Apis to assemble.”
Tibetan medicine's theory is thought: the trouble diabetes are relevant to " three categories of etiologic factors " imbalance of self body.Under normal circumstances, human body " dragon " (being equivalent to wind, gas), " red bar " (refer to gallbladder, fire, the root that causes all heat symptom-complex diseases), " Baconic " (refer to water, soil, the root that causes all sympotoms caused by cold factors diseases) " three categories of etiologic factors " be in poised state, could keep the normal operation of body function.the pathogenic factor of diabetes is because serious unbalance appears in human body " three categories of etiologic factors ", usually comparatively significant performance is that " red bar " and " dragon " contained partially, " Baconic " is on the weak side, caused seven large cereal nutrients of human body (precise and tiny, blood, muscle, fat, skeleton, marrow, seminal fluid) can not normally decompose, excretion and conveying, dirty thing in blood is assembled too much, the vitals function that causes the human bodies such as heart kidney is impaired, show as clinically xerostomia easily hungry, urine urgency-frequency, weak dreaminess, the symptom such as become thin, simultaneously with heating, visual deterioration, the symptoms such as skin pruritus.
The Tibetan medicine reaches and falls " red bar " and " dragon " by conditioning, balance " three categories of etiologic factors ", and righting " Baconic " is purpose, make seven large cereal nutrients in body be decomposed normally and drain, reduce harmful composition in blood, make pancreas obtain nutrition, islet function progressively recovers; Regulate simultaneously dietary, the custom of making the life better, finally reach nutrition pancreas, reduce blood glucose, improve complication, improve the purpose of patient's live and work quality.
The medicine of diabetes comprises orally-taken blood sugar reducing medicine and insulin at present.The orally-taken blood sugar reducing medicine comprises: (1) sulfonylurea drugs; (2) biguanides; (3) meals glucose regulator; (4) alpha-glucosidase inhibitor; (5) aldose reductase inhibitor; (6) Study of Thiazolidinedione derivatives as Insulin Sensitizer; (7) other drug.
According to the difference of hypoglycemic mechanism, the orally-taken blood sugar reducing medicine can be divided into Drugs Promoting Insulin Secretion (sulphanylureas, meals glucose regulator), euglycemic agent (biguanides, Study of Thiazolidinedione derivatives as Insulin Sensitizer) and other drug (alpha-glucosidase inhibitor, non-insulin glucose-lowering hormonal agents for diabetes).
Sulfonylurea drugs is divided into the three generations, and the first generation comprises tolbutamide, chlorpropamide, tolazamide and acetohexamide; In generation, comprise glibenclamide, glipizide, glibornuride, gliclazide and gliquidone; The third generation just has glimepiride.
Biguanides comprises metformin and phenformin, and the latter abroad stops using at present, domestic also seldom use.
Meals glucose regulator has repaglinide and Nateglinide.
Alpha-glucosidase inhibitor has acarbose and voglibose.
Study of Thiazolidinedione derivatives as Insulin Sensitizer has rosiglitazone, troglitazone and pioglitazone.
The non-insulin glucose-lowering hormonal agents for diabetes has Pramlintide and Exenatide.
The untoward reaction of Remedies for diabetes:
1, insulin:
The untoward reaction of insulin has: (1) anaphylaxis, and use the patient of insulin urticaria and vasodilation can occur in the injection site; (2) hypoglycemic reaction; (3) insulin resistant; (4) injection site is lipoatrophy or hypertrophy; (5) refraction of eye imbalance.
2, sulfonylurea drugs:
The untoward reaction of sulfonylurea drugs: accidental hypoglycemia, diarrhoea can be arranged, feel sick, vomit, have a headache, have a stomachache or discomfort, erythra is more rare, and rare and serious have jaundice, liver function injury, granulocytopenia (showing as pharyngalgia, heating, infection), a thrombocytopenia (showing as hemorrhage, purpura) etc.
3, biguanides:
The untoward reaction of biguanides is modal is: gastrointestinal reaction, show as inappetence, nausea,vomiting,diarrhea, stomachache, mouthful in metallic taste etc.Sometimes the patient have weak, tired, lose weight, dizziness and erythra etc.
4, meals glucose regulator:
The untoward reaction of meals glucose regulator has: hypoglycemia, visual abnormality, gastrointestinal reaction, allergic rash, pruritus and urticaria etc.Only a few patient the liver transaminase occurs and increases, and its degree is light and be one to cross property, seldom causes drug withdrawal.
5, Study of Thiazolidinedione derivatives as Insulin Sensitizer:
The untoward reaction of Study of Thiazolidinedione derivatives as Insulin Sensitizer comprises: (1) anemia; (2) cardiovascular system reaction; (3) neural psychiatric system reaction; (4) hypoglycemic reaction; (5) gastrointestinal reaction etc.
6, non-insulin glucose-lowering hormonal agents for diabetes:
The non-insulin glucose-lowering hormonal agents for diabetes also has some untoward reaction, wherein feels sick the most common, and after the severe hypoglycemia event easily betides and uses in 3h, anorexia, vomiting, weak and dizzy etc. also can appear in the patient.
Treatment diabetes Chinese patent medicine commonly used mainly contains following several at present:
(1) diabetes pill; (2) JIANGTANGSHU; (3) YUQUAN WAN; (4) blood sugar lowering first sheet; (5) Ganluxiaoke capsules; (6) LIUWEI DIHUANG WAN, MAIWEIDIHUANGWAN; (7) SHIHUYEGUANG WAN; (8) Radix Rehmanniae Pilulae for Improving Eyesight; (9) SHENQI JIANGTANG sheet; (10) Kelening capsule; (11) the clever sheet of quenching one's thirst; (12) JINQI JIANGTANG PIAN; (13) TANGMAIKANG KELI; (14) ten eight flavor Fructus Chebulae diuresis balls.But the curative effect of these Chinese medicine preparation still can not be satisfactory however.
Therefore, still there is tight demand in people's Chinese medicine (Tibetan medicine) preparation that curative effect is better treated diabetes.Up to now, also do not find the report of any relevant pharmaceutical composition of the present invention.The inventor is through research repeatedly, and the checking repeatedly by animal and clinical trial, has finally found the Tibetan medicine oral drugs (for a long time U.S. No. 1 diabetic tea) that the treatment of better curative effect diabetes are arranged, thereby has completed the present invention.
[summary of the invention]
The object of the invention just is to provide a kind of medicine of more effectively treating diabetes.
Another object of the present invention has been to provide the preparation method of this medicine.
Medicine of the present invention is a kind of Tibetan medicine, is formed or is comprised of active component and pharmaceutically acceptable adjuvant by active component, and wherein said active component is to be made by following bulk drugs: Rhododendron, Semen Myristicae, Parmelia saxatilis Ach., Herba Urticae triangularis.
It has selected Rhododendron, Semen Myristicae, Parmelia saxatilis Ach. and Herba Urticae triangularis to make up as crude drug, and wherein (1) Rhododendron is dried floral and the leaf of ericad Rhododendron Rhododendron anthopogonoides Maxim..Nature and flavor are sweet, puckery, flat, and clearing heat for detumescence is arranged, the function of the kidney invigorating; Be used for tracheitis, emphysema, edema, physical weakness and water and soil are uncomfortable, dyspepsia, gastroptosis, flatulence, the skin ulcer pestilence is controlled in external.(2) Semen Myristicae is the dry kernel of myristicaceae plant Semen Myristicae Myristica fragrans Houtt..Nature and flavor are hot, warm, warming middle-JIAO arranged, antidiarrheal, the function of circulation of qi promoting; Be used for the deficiency and coldness chronic diarrhea, inappetence, coldness and pain in the epigastrium rushes down antiinflammatory on having, and anti-platelet aggregation is anticancer, and is antibiotic waits pharmacological action.(3) Parmelia saxatilis Ach. is the lichens Flos Mume clothing Flos Mume clothing platymiscium lichen Parmelia saxatilis of section (L.) Ach.[Lichen saxatilis L.].Nature and flavor are sweet, flat, return liver, kidney channel, have invigrating kidney, make eye bright, and hemostasis, the function of eliminating damp, detoxifying; Be used for blurred vision, lumbocrural pain is spitted blood, metrorrhagia, jaundice, skin ulcer tinea etc.(4) Herba Urticae triangularis is Urticaceae Urtica plant Urtica macrorrhiza Hand.-Mazz. Urtica macrorrhiza Hand.-Mazz., with all herbal medicine.Nature and flavor are bitter, hot, and temperature has wind-damp dispelling, spasmolytic, detoxifcation, heat clearing away cold relieving, the function that activating QI helps digestion; Be used for controlling Baconic, red bar disorders of blood, rheumatic arthritis, hypertension, infantile convulsion, puerperal convulsion, urticaria, venom.Make each efficacy of drugs produce synergism these drug regimens, thereby can effectively treat diabetes.
The consumption of medicine of the present invention (for a long time U.S. No. 1 diabetic tea) component is also groped to sum up to draw through the inventor in a large number, and each amounts of components is for all to have good therapeutic effect in the following weight parts scope:
0.2～0.4 part of 0.5～1.5 part of Rhododendron, 0.5～1.5 part of Semen Myristicae, 0.5～1.5 part of Parmelia saxatilis Ach., 1～3 part of Herba Urticae triangularis and brick tea.
Be preferably: 0.26 part of 1 part of Rhododendron, 1 part of Semen Myristicae, 1 part of Parmelia saxatilis Ach., 2 parts of Herba Urticae triangulariss and brick tea.
The preparation of medicine activity component of the present invention can be the crude drug convection drying of above-mentioned consumption to be pulverized make; Also the crude drug of above-mentioned consumption can be adopted the conventional method of Chinese medicine preparation such as decoction and alcohol sedimentation technique or ethanol extract from water precipitation (referring to " pharmaceutics of Chinese drugs " 73-74 page of Cao Chunlin chief editor, Science and Technology of Shanghai publishing house publishes in November, 1986) to make.
The active component of medicine of the present invention can add conventional adjuvant required when preparing dosage form, as binding agent etc. with the method for Chinese medicinal of routine (referring to Cao Chunlin chief editor's " pharmaceutics of Chinese drugs ", Science and Technology of Shanghai publishing house publishes in November, 1986) be prepared into medicinal tea, comprise block medicinal tea, packed medicinal tea and decoct medicinal tea.
Medicine of the present invention has enriching yin and nourishing kidney, QI invigorating lung moistening, the function of promoting the production of body fluid and quenching one's thirst.Be used for the treatment of diabetes.Polydipsia, polyphagia, the polyuria that the Tibetan medicine is used for being caused by " dragon " imbalance, become thin, the diabetess such as glucose in urine and blood sugar increasing.The traditional Chinese medical science is used for the diabetes due to deficiency of both QI and YIN.
The usage and dosage of medicine of the present invention (for a long time U.S. No. 1 diabetic tea) is: boiled water brews to be drunk.A 2g, 1～4 time on the one.
[specific embodiment]
Come by the following examples further to set forth the preparation method of medicine of the present invention.
The block medicinal tea preparation of [embodiment 1] medicine of the present invention:
Take Rhododendron 380g, Semen Myristicae 380g, Parmelia saxatilis Ach. 380g and Herba Urticae triangularis 760g, jointly be ground into coarse powder after mixing, add brick tea 100g, mixing is pressed into bulk, namely gets block medicinal tea, is called U.S. No. 1 diabetic tea of a specified duration.
The packed medicinal tea preparation of [embodiment 2] medicine of the present invention:
Take Rhododendron 350g, Semen Myristicae 400g, Parmelia saxatilis Ach. 250g and Herba Urticae triangularis 850g, jointly be ground into coarse powder after mixing, add brick tea 150g, mixing is packed into and is drunk tea bag, namely gets packed medicinal tea.
The decoction medicinal tea preparation of [embodiment 3] medicine of the present invention:
Take Rhododendron 450g, Semen Myristicae 350g, Parmelia saxatilis Ach. 400g and Herba Urticae triangularis 720g, jointly be ground into coarse powder after mixing, add brick tea 80g, mixing in the bag of packing into, namely gets the decoction medicinal tea.
Below further set forth the beneficial effect of medicine of the present invention (for a long time U.S. No. 1 diabetic tea) by test example, these test examples have comprised pharmacodynamics test and the clinical observation on the therapeutic effect test of medicine of the present invention (for a long time U.S. No. 1 diabetic tea).
[test example 1] medicine of the present invention (for a long time U.S. No. 1 diabetic tea) reaches the pharmacodynamics test that lumbar injection 25% glucose solution rat carbohydrate tolerance is affected on the large and small Mus blood sugar influence of alloxan diabetes:
Test material:
Animal NIH mice Wistar rat provides by animal housing of Part of Qinghai Plateau biological study institute.
Anthology invention medicine (for a long time U.S. No. 1 diabetic tea); Glibenclamide tablet (Glibenclamide Tablets), the 2.5mg/ sheet, lot number: 20090712, metal and stone pharmacy head factory in Shantou is produced; JIANGZHILING PIAN (phenformin hydrochloride tablet), the 25mg/ sheet, lot number: 20090823, Jintan City, Jiangsu Province pharmaceutical factory produces; Alloxan, sigma company produces; Blood sugar detection test kit (glucose oxidase method), lot number: 20090517, east, Wenzhou bowl biological engineering company limited is produced; Serum insulin is put and exempted from testing cassete, lot number: 1608-200904, China Atomic Energy Science Research Institute's coordination rope institute provides.
1, the impact of medicine of the present invention (for a long time U.S. No. 1 diabetic tea) on the alloxan diabetes rat blood sugar:
Experimental technique: get 50 of the male rats of body weight 200～250g, except Normal group, all the other rats are with the alloxan aqueous solution tail vein injection of 50mg/kg, and after drinking-water is raised 72h routinely, water 3h is can't help in fasting, surveys blood glucose value from the rat tail vein blood sampling.The rat of above-mentioned injection alloxan is divided into 4 groups by blood sugar level, 10 every group.Wherein organize respectively ig and give medicine of the present invention (for a long time U.S. No. 1 diabetic tea) and be crude drug 8,2g/kg for 2; 1 group of ig gives JIANGZHILING PIAN 100mg/kg; Yu 2 groups be Normal group and model control group, ig equivalent distilled water.Be administered once every day, continuous 7 days.1h blood glucose value after the administration of mensuration last.With t method of inspection statistical experiment result, the results are shown in Table 1.
Table 1 medicine of the present invention (for a long time U.S. No. 1 diabetic tea) on the impact of alloxan diabetes rat blood sugar (± SD)
Annotate: compare with matched group,
△P＜0.05
△ △P＜0.01;
Compare with model group,
*P＜0.05
*P＜0.01.
Experimental result: medicine of the present invention (for a long time U.S. No. 1 diabetic tea) 8,2g/kg has obvious reducing effect to the alloxan diabetes rat blood sugar.
2, the impact of medicine of the present invention (for a long time U.S. No. 1 diabetic tea) on the alloxan diabetes mouse blood sugar:
Experimental technique: get 50 of the male mices of body weight 22～26g, except Normal group, all the other mices are with the alloxan aqueous solution tail vein injection of 60mg/kg, and after drinking-water is raised 72h routinely, water 3h is can't help in fasting, surveys blood glucose value from the mouse tail vein blood sampling.The mice of above-mentioned injection alloxan is divided into 4 groups by blood sugar level, 10 every group.Wherein organize respectively ig and give medicine of the present invention (for a long time U.S. No. 1 diabetic tea) and be crude drug 8,2g/kg for 2; 1 group of ig gives JIANGZHILING PIAN 100mg/kg; Yu 2 groups be Normal group and model control group, ig equivalent distilled water.Be administered once every day, continuous 7 days.1h blood glucose value after the administration of mensuration last.With t method of inspection statistical experiment result, the results are shown in Table 2.
Table 2 medicine of the present invention (for a long time U.S. No. 1 diabetic tea) on the impact of alloxan diabetes mouse blood sugar (± SD)
Annotate: compare with matched group,
△P＜0.05
△ △P＜0.01;
Compare with model group,
*P＜0.05
*P＜0.01.
Experimental result: medicine of the present invention (for a long time U.S. No. 1 diabetic tea) 8,2g/kg has obvious reducing effect to the alloxan diabetes mouse blood sugar.
3, the impact of medicine of the present invention (for a long time U.S. No. 1 diabetic tea) on lumbar injection 25% glucose solution rat carbohydrate tolerance:
Experimental technique: get 50 of the rats of body weight 200～250g, male and female half and half are divided into 5 groups at random, 10 every group.Water 24h is can't help in fasting, its blood glucose value (0 ') of tail vein blood side, and then administration is wherein organized respectively ig and is given medicine of the present invention (for a long time U.S. No. 1 diabetic tea) and press crude drug 8,4,2g/kg for 3; 1 group of ig gives glibenclamide tablet 25mg/kg; Yu 1 group be Normal group, ig equivalent distilled water.1h rats by intraperitoneal injection 25% glucose solution 10ml/kg after administration surveys its blood glucose value respectively at 30 ', 60 ', 120 ' each rat tail vein blood sampling after giving sugar.With t method of inspection statistical experiment result, the results are shown in Table 3.
Table 3 medicine of the present invention (for a long time U.S. No. 1 diabetic tea) on the impact of lumbar injection 25% glucose solution rat carbohydrate tolerance (± SD)
Annotate: compare with matched group,
*P＜0.05
*P＜0.01.
Experimental result: medicine of the present invention (for a long time U.S. No. 1 diabetic tea) is pressed crude drug 8,4, and 2g/kg is to the lumbar injection 25% glucose solution rat carbohydrate tolerance effect of being significantly improved.
Experimental result shows, medicine of the present invention (for a long time U.S. No. 1 diabetic tea) has obvious reducing effect to the large and small Mus hyperglycemia of alloxan diabetes; To the lumbar injection 25% glucose solution rat carbohydrate tolerance effect of being significantly improved.Therefore, medicine of the present invention (for a long time U.S. No. 1 diabetic tea) is clinical has certain pharmacology's foundation for " diabetes " treatment.
[test example 2] medicine of the present invention (for a long time U.S. No. 1 diabetic tea) treatment diabetes clinical observation on the therapeutic effect:
Physical data:
My institute uses medicine of the present invention (for a long time U.S. No. 1 diabetic tea) treatment Diabetes Clinic patient 72 examples.Wherein, male 32 examples, female's 40 examples; 46～69 years old age, average 58.5 years old; The course of disease 3 months～13 years; Accompanied with hypertension patient 13 examples, hyperlipemic patients 17 examples, cardiac's 12 examples, menoxenia patient 9 examples, skin pruritus patient's 8 examples; 38 routine patients once carried out western medical treatment, and effect is not good enough.
Therapeutic Method:
Adopt medicine of the present invention (for a long time U.S. No. 1 diabetic tea), boiled water brews to be drunk.A 2g, 1～4 time on the one.30 days is a course for the treatment of.
The clinical efficacy evaluation criteria:
Carry out efficacy evaluation according to " tcm internal medicine Illnesses Diagnoses standard " that State Administration of Traditional Chinese Medicine promulgates.
Produce effects: clinical symptom disappearance, continuous 3 months prompting fasting glucose of lab testing are down in 6.66mmol/L, and glucose in urine is turned out cloudy;
Effectively: patient clinical sx↓ or disappearance, lab testing prompting fasting glucose descends;
Invalid: the patient clinical symptom is without improvement, and lab testing prompting fasting glucose is not fallen.
Clinical observation result: 72 routine patients are remarkable through 1 course of therapy effect, and total effective rate reaches 95.83%.See Table 4.
Clinical efficacy (example) after table 4 medicine of the present invention (for a long time U.S. No. 1 diabetic tea) treatment
This group patient uses medicine of the present invention (for a long time U.S. No. 1 diabetic tea) treatment patient 72 examples, and total effective rate reaches 95.83%, and visible medicine of the present invention (for a long time U.S. No. 1 diabetic tea) treatment diabetes can obtain satisfactory effect, and clinic is used.
Claims (7)
1. medicine for the treatment of diabetes, it is characterized in that it is comprised of active component or is comprised of active component and pharmaceutically acceptable adjuvant, wherein said active component is to be made by the crude drug of following weight portion: 0.2～0.4 part of 0.5～1.5 part of Rhododendron, 0.5～1.5 part of Semen Myristicae, 0.5～1.5 part of Parmelia saxatilis Ach., 1～3 part of Herba Urticae triangularis and brick tea.
2. medicine according to claim 1, wherein said active component is to be made by the crude drug of following weight portion: 0.26 part of 1 part of Rhododendron, 1 part of Semen Myristicae, 1 part of Parmelia saxatilis Ach., 2 parts of Herba Urticae triangulariss and brick tea.
3. medicine according to claim 1 and 2, it is peroral dosage form.
4. medicine according to claim 3, it is medicinal tea.
5. the preparation method of the described medicine of claim 1, it comprises the following steps: to take the raw material of following weight portion: 0.5～1.5 part of Rhododendron, 0.5～1.5 part of Semen Myristicae, 0.5～1.5 part of Parmelia saxatilis Ach., 1～3 part of Herba Urticae triangularis, mix, jointly be ground into coarse powder; Add 0.2～0.4 part of brick tea, mixing is made active component.
6. the preparation method of the described medicine of claim 1, it comprises the following steps: to take the raw material of following weight portion: 0.5～1.5 part of Rhododendron, 0.5～1.5 part of Semen Myristicae, 0.5～1.5 part of Parmelia saxatilis Ach., 1～3 part of Herba Urticae triangularis, mix, adopt decoction and alcohol sedimentation technique or ethanol extract from water precipitation to make active component.
7. according to the described preparation method of claim 5 or 6, wherein take the raw material of following weight portion: 0.26 part of 1 part of Rhododendron, 1 part of Semen Myristicae, 1 part of Parmelia saxatilis Ach., 2 parts of Herba Urticae triangulariss and brick tea.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110289631 CN102366480B (en) | 2011-09-28 | 2011-09-28 | Medicine for treating diabetes and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110289631 CN102366480B (en) | 2011-09-28 | 2011-09-28 | Medicine for treating diabetes and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102366480A CN102366480A (en) | 2012-03-07 |
| CN102366480B true CN102366480B (en) | 2013-05-08 |
Family
ID=45759100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110289631 Active CN102366480B (en) | 2011-09-28 | 2011-09-28 | Medicine for treating diabetes and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102366480B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103585312B (en) * | 2013-10-31 | 2016-04-20 | 黄彩峰 | A kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof |
| CN106581646A (en) * | 2016-11-03 | 2017-04-26 | 广州凯耀资产管理有限公司 | Oral insulin composition |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101700397A (en) * | 2009-11-10 | 2010-05-05 | 尼玛次仁 | Tibetan medicine composite for treating diabetes and preparation method of preparation thereof |
-
2011
- 2011-09-28 CN CN 201110289631 patent/CN102366480B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101700397A (en) * | 2009-11-10 | 2010-05-05 | 尼玛次仁 | Tibetan medicine composite for treating diabetes and preparation method of preparation thereof |
Non-Patent Citations (4)
| Title |
|---|
| 凉山风味石花菜肴;食为天者;《四川烹饪》;19980131(第01期);29 * |
| 荨麻属植物的研究进展;闵勇等;《时珍国医国药》;20100930(第09期);2345-2346 * |
| 闵勇等.荨麻属植物的研究进展.《时珍国医国药》.2010,(第09期),2345-2346. |
| 食为天者.凉山风味石花菜肴.《四川烹饪》.1998,(第01期),29. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102366480A (en) | 2012-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102366595B (en) | Medicine for treating diabetes and preparation method thereof | |
| CN100374140C (en) | Health-care for diabetes | |
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN101428113A (en) | Traditional Chinese medicine preparation for treating type II diabetes and preparation method thereof | |
| CN103768407B (en) | A kind of hypoglycemic compound capsule and preparation method thereof | |
| CN102813870B (en) | Chinese herbal compound preparation used for treating alcoholism and gout and preparation method and application thereof | |
| CN100493572C (en) | Composition of medication for treating diabetes | |
| CN101085039B (en) | Composition for preventing and treating diabetes (hyperglycaemia) and its preparation method | |
| CN102872423B (en) | Traditional Chinese medicine compound for treating glycuresis and preparation method thereof | |
| CN102366480B (en) | Medicine for treating diabetes and preparation method thereof | |
| CN102366540B (en) | Medicine for treating diabetes and its preparation method | |
| CN109498731A (en) | A kind of tonifying speen and tonifying kidney tune sugar-pill and preparation method thereof for treating diabetes B Pishenqixu syndrome | |
| CN102366481B (en) | Medicine for treating diabetes and preparation method thereof | |
| CN102366596B (en) | Medicine for treating diabetes and preparation method thereof | |
| CN103751558B (en) | A kind of compound antihypelipidemic pill and preparation method thereof | |
| CN103055176A (en) | Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof | |
| CN103393938B (en) | Traditional Chinese medicine composition for reducing blood sugar | |
| CN102274396A (en) | Traditional Chinese medicine for treating diabetic nephropathy and preparation method thereof | |
| CN102366443B (en) | Medicine for treating diabetes and preparation method thereof | |
| CN110680861A (en) | A Chinese medicinal composition for treating diabetes | |
| CN104815140A (en) | Composition for preventing or/and treating diabetes and preparation method of composition | |
| CN109010621A (en) | A kind of Chinese medicine composition that treating diabetes, preparation method and applications | |
| CN100398123C (en) | Medicine for treating diabetes of blood stasis complicated kidney spleen deficiency type | |
| CN104689151A (en) | Traditional Chinese medicine composition for treating diabetes and use of composition | |
| CN102309635B (en) | Traditional Chinese medicine preparation for treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine for treating diabetes and its preparing process Effective date of registration: 20200525 Granted publication date: 20130508 Pledgee: Qinghai Chuangqi Finance Leasing Co.,Ltd. Pledgor: Jiumei Pengcuo Registration number: Y2020630000001 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210517 Granted publication date: 20130508 Pledgee: Qinghai Chuangqi Finance Leasing Co.,Ltd. Pledgor: Jiumei Pengcuo Registration number: Y2020630000001 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine for treating diabetes and preparation method thereof Effective date of registration: 20210602 Granted publication date: 20130508 Pledgee: Qinghai Chuangqi Finance Leasing Co.,Ltd. Pledgor: Jiumei Pengcuo Registration number: Y2021630000003 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230608 Granted publication date: 20130508 Pledgee: Qinghai Chuangqi Finance Leasing Co.,Ltd. Pledgor: Jiumei Pengcuo|Qinghai Jiumei Zang Drug Drug Co.,Ltd. Registration number: Y2021630000003 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231008 Address after: Room 1231, Building 11, No. 90 Wusi West Road, Chengxi District, Xining City, Qinghai Province, 810000 Patentee after: Yang Cuoji Address before: 810003 18, No. three, Qinghai biological science and Technology Industrial Park, Qinghai, Xining Patentee before: Jiumei Pengcuo |
|
| TR01 | Transfer of patent right |